Safety and efficacy of atrial antitachycardia pacing in congenital heart disease

Kramer, Collin C.; Maldonado, Jennifer; Olson, Mark D.; Gingerich, Jean; Ochoa, Luis; Law, Ian H.

doi:10.1016/j.hrthm.2017.12.016

Cited by 36 publications

(11 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…93,94 Kramer et al revealed that implantation of an atrial antitachycardia pacing device was associated with reduced direct current cardioversion burden, and the overall success rate of A-ATP was 69% in a cohort of 91 patients with congenital heart disease and ATAs. 95 Although there are few studies assessing the efficacy of A-ATP in patients with an ICD or a CRT device, Crossley et al analyzed the data obtained from a large device database of a remote monitoring system (Medtronic CareLink TM ) and reported the effectiveness of the second generation of A-ATP. 96 Among 1,062 patients with an ICD, the use of the second generation of A-ATP was associated with reduced risk of ≥7 days of ATAs as compared with no use, even after controlling for other covariates (HR: 0.58, 95% CI: 0.43-0.77).…”

Section: Role Of Cardiac Implantable Electrical Devices In the Termin...mentioning

confidence: 99%

JCS/JHRS 2021 guideline focused update on non‐pharmacotherapy of cardiac arrhythmias

Nogami¹,

Kurita²,

Kusano³

et al. 2022

Journal of Arrhythmia

View full text Add to dashboard Cite

Section: Role Of Cardiac Implantable Electrical Devices In the Termin...mentioning

confidence: 99%

JCS/JHRS 2021 guideline focused update on non‐pharmacotherapy of cardiac arrhythmias

Nogami¹,

Kurita²,

Kusano³

et al. 2022

Journal of Arrhythmia

View full text Add to dashboard Cite

“…Atrial anti-tachycardia pacing (ATP) from implantable cardiac devices effectively suppresses AT in patients with CHD. 13 In this case, we used a single chamber atrial pacemaker, which cannot automatically deliver ATP. Manual ATP will be considered if the AT recurs.…”

Section: Discussionmentioning

confidence: 99%

Pacemaker implantation via femoral vein and successful arrhythmia management in an elderly patient with Fontan circulation: a case report

Mizuno

Nishii

Morita

et al. 2022

European Heart Journal - Case Reports

View full text Add to dashboard Cite

Background The frequency of arrhythmias increases after the Fontan operation over time; atrial tachycardia (AT) and sinus node dysfunction (SND) are frequently observed. Case summary Our patient was 63-year-old woman who underwent a lateral tunnel Fontan operation for double outlet right ventricle at age 36. She experienced paroxysmal AT for one year, and antiarrhythmic medication was not feasible due to symptomatic SND. Computed tomography revealed a 45 mm-sized thrombus in the high right atrium (RA). The patient had three coexisting conditions: paroxysmal AT, symptomatic SND and the RA thrombus, for which total cavopulmonary connection conversion and epicardial PMI would have been effective; however, given her age and comorbidities, surgical treatment was considered high-risk. Catheter ablation was avoided because of the RA thrombus. Finally, a transvenous pacemaker was implanted via the right femoral vein to avoid the RA thrombus and severe venous tortuosity from the left subclavian vein to the RA. After PMI, the patient was prescribed amiodarone and bisoprolol for AT suppression. AT occurred once in the third month after discharge. We increased the dose of amiodarone, and she has been tachycardia-free. Discussion Transvenous PMI must be considered in cases where open thoracic surgery or catheter ablation cannot be performed. This is the first report of transvenous PMI via the right femoral vein and successful AT and SND management in an elderly Fontan patient.

show abstract

“…93, 94 Kramer et al revealed that implantation of an atrial antitachycardia pacing device was associated with reduced direct current cardioversion burden, and the overall success rate of A-ATP was 69% in a cohort of 91 patients with congenital heart disease and ATAs. 95 Although there are few studies assessing the efficacy of A-ATP in patients with an ICD or a CRT device, Crossley et al analyzed the data obtained from a large device database of a remote monitoring system (Medtronic CareLink TM ) and reported the effectiveness of the second generation of A-ATP. 96 Among 1,062 patients with an ICD, the use of the second generation of A-ATP was associated with reduced risk of ≥7 days of ATAs as compared with no use, even after controlling for other covariates (HR: 0.58, 95% CI: 0.43-0.77).…”

Section: Role Of Cardiac Implantable Electrical Devices In the Termination And Prevention Of Atrial Arrhythmiasmentioning

confidence: 99%

JCS/JHRS 2021 Guideline Focused Update on Non-Pharmacotherapy of Cardiac Arrhythmias

Nogami

Kurita

Kusano

et al. 2022

Circ J

View full text Add to dashboard Cite

AVNRT atrioventricular nodal reentrant tachycardia BARC Bleeding Academic Research Consortium CBA cryoballoon ablation CIED cardiac implantable electronic device COR class of recommendation CRT cardiac resynchronization therapy CRT-D cardiac resynchronization therapy defibrillator CRT-P cardiac resynchronization therapy pacemaker CT computed tomography DAP dose-area product DAPT dual antiplatelet therapy DNAR Do Not Attempt Resuscitation DOAC direct oral anticoagulant EBM evidence-based medicine ESC European Society of Cardiology JCS GUIDELINES

show abstract

Safety and efficacy of atrial antitachycardia pacing in congenital heart disease

Cited by 36 publications

References 13 publications

JCS/JHRS 2021 guideline focused update on non‐pharmacotherapy of cardiac arrhythmias

JCS/JHRS 2021 guideline focused update on non‐pharmacotherapy of cardiac arrhythmias

Pacemaker implantation via femoral vein and successful arrhythmia management in an elderly patient with Fontan circulation: a case report

JCS/JHRS 2021 Guideline Focused Update on Non-Pharmacotherapy of Cardiac Arrhythmias

Contact Info

Product

Resources

About